Get the Stockscreener App
3.85
3.63%
-0.145
Clene Inc stock is traded at $3.85, with a volume of 122.50K.
It is down -3.63% in the last 24 hours and down -27.08% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$3.995
Open:
$3.92
24h Volume:
122.50K
Relative Volume:
1.43
Market Cap:
$49.47M
Revenue:
$134.00K
Net Income/Loss:
$-33.51M
P/E Ratio:
-1.2003
EPS:
-3.2074
Net Cash Flow:
$-18.15M
1W Performance:
-8.98%
1M Performance:
-27.08%
6M Performance:
-30.13%
1Y Performance:
-35.29%
1-Day Range:
$3.72
$4.00
1-Week Range:
$3.72
$4.42
52-Week Range:
$3.72
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.85 | 56.15M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN) - The Globe and Mail
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - MarketBeat
Clene at Emerging Growth Conference: FDA path takes shape for ALS drug - Investing.com
CLNN: CNM-Au8 shows strong survival and functional benefits in ALS, with NDA submission imminent - TradingView
Clene (CLNN) Move: Climbs 0.49% to $4.11 on the Day; Technical Setup: $3.90 and $4.32 Define the Nearby Reference Levels for the Current SessionVWAP Deviation - vinanet.vn
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream - Investing News Network
HC Wainwright Issues Negative Estimate for Clene Earnings - MarketBeat
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene(CLNN) Stock Options Chain | Quotes & News - Moomoo
Clene to Present at the Emerging Growth Conference - Investing News Network
Clene stock holds at buy as H.C. Wainwright keeps $31 target By Investing.com - Investing.com Australia
Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - Kalkine Media
Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media
CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus
Clene earnings missed by $0.75, revenue topped estimates - Investing.com
Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat
Clene Releases Q2 2026 Financial Results - AlphaStreet
Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan
Clene Inc. (CLNN) grants 3,195 stock options to director Matthew Kiernan - Stock Titan
Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan
Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan
Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan
Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan
Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget
Clene Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Form 8K Clene Inc. For: 14 August By Investing.com - Investing.com Canada
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights - The Manila Times
Clene Inc. (NASDAQ: CLNN) widens Q2 loss while preparing accelerated ALS NDA - Stock Titan
ALS patients whose nerve marker declined or stabilized lived longer, Clene says - Stock Titan
CLNN: Net loss widened to $13.4M in Q2 2026, with ongoing funding concerns and rising R&D costs - TradingView
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CLNN Q2'26 Earnings: EPS estimate is (0.37) USD - TradingView
CLNN Q1 2026 Earnings: Narrower-than-Expected Loss of $0.27 per Share Lifts SharesEarnings Call Transcript - Vinanet
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS - MarketBeat
Clene Nanomedicine at canaccord growth conference: FDA path in focus By Investing.com - Investing.com Canada
Clene Inc. (CLNN) holder Ugwumba exits, reports 0% beneficial stake - Stock Titan
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Clene reports survival benefit in ALS patients with NfL response By Investing.com - Investing.com UK
Empery Asset Management, LP Buys Clene Inc (CLNN) -- Shares Look 486% Overvalued on GF Value - GuruFocus
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval - Investing News Network
Clene Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Clene reports survival benefit in ALS patients with NfL response - Investing.com
Form 8K Clene Inc. For: 10 August By Investing.com - Investing.com Australia
Clene (CLNN) ties CNM-Au8 ALS survival gains to NfL biomarker for planned NDA - Stock Titan
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):